 Recombinant Fusion Proteins
"Recombinant Fusion Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
| Descriptor ID |
D011993
|
| MeSH Number(s) |
D12.776.828.300
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Recombinant Fusion Proteins".
Below are MeSH descriptors whose meaning is more specific than "Recombinant Fusion Proteins".
This graph shows the total number of publications written about "Recombinant Fusion Proteins" by people in this website by year, and whether "Recombinant Fusion Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 12 | 12 | | 1996 | 5 | 17 | 22 | | 1997 | 4 | 10 | 14 | | 1998 | 1 | 14 | 15 | | 1999 | 2 | 13 | 15 | | 2000 | 2 | 22 | 24 | | 2001 | 4 | 28 | 32 | | 2002 | 0 | 26 | 26 | | 2003 | 4 | 11 | 15 | | 2004 | 3 | 20 | 23 | | 2005 | 4 | 12 | 16 | | 2006 | 3 | 20 | 23 | | 2007 | 1 | 8 | 9 | | 2008 | 4 | 14 | 18 | | 2009 | 4 | 10 | 14 | | 2010 | 5 | 22 | 27 | | 2011 | 6 | 13 | 19 | | 2012 | 6 | 9 | 15 | | 2013 | 8 | 10 | 18 | | 2014 | 5 | 9 | 14 | | 2015 | 10 | 12 | 22 | | 2016 | 6 | 12 | 18 | | 2017 | 7 | 8 | 15 | | 2018 | 2 | 8 | 10 | | 2019 | 4 | 1 | 5 | | 2020 | 2 | 7 | 9 | | 2021 | 5 | 5 | 10 | | 2022 | 0 | 4 | 4 | | 2023 | 1 | 3 | 4 | | 2024 | 2 | 1 | 3 | | 2025 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Recombinant Fusion Proteins" by people in Profiles.
-
McMahon C, Raddi MG, Mohan S, Santini V. New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes. Am Soc Clin Oncol Educ Book. 2025 Jun; 45(3):e473654.
-
Hoeper MM, Gomberg-Maitland M, Badesch DB, Gibbs JSR, Gr?nig E, Kopec G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Manimaran S, Wang X, Miller B, Cornell AG, de Oliveira Pena J, Ghofrani HA, Humbert M. Efficacy and safety of the activin signalling inhibitor, sotatercept, in a pooled analysis of PULSAR and STELLAR studies. Eur Respir J. 2025 May; 65(5).
-
Bjornstad P, Arslanian SA, Hannon TS, Zeitler PS, Francis JL, Curtis AM, Turfanda I, Cox DA. Dulaglutide and Glomerular Hyperfiltration, Proteinuria, and Albuminuria in Youth With Type 2 Diabetes: Post Hoc Analysis of the AWARD-PEDS Study. Diabetes Care. 2024 Sep 01; 47(9):1617-1621.
-
Liu A, Anderson KE, Levy J, Johnson TV, Polsky D, Anderson G. Macular Degeneration Drug Prescribing Patterns After Step Therapy Introduction in Medicare Advantage. JAMA Health Forum. 2024 Aug 02; 5(8):e242446.
-
Albain KS, Yau C, Petricoin EF, Wolf DM, Lang JE, Chien AJ, Haddad T, Forero-Torres A, Wallace AM, Kaplan H, Pusztai L, Euhus D, Nanda R, Elias AD, Clark AS, Godellas C, Boughey JC, Isaacs C, Tripathy D, Lu J, Yung RL, Gallagher RI, Wulfkuhle JD, Brown-Swigart L, Krings G, Chen YY, Potter DA, Stringer-Reasor E, Blair S, Asare SM, Wilson A, Hirst GL, Singhrao R, Buxton M, Clennell JL, Sanil A, Berry S, Asare AL, Matthews JB, DeMichele AM, Hylton NM, Melisko M, Perlmutter J, Rugo HS, Symmans WF, Van't Veer LJ, Yee D, Berry DA, Esserman LJ. Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery. Clin Cancer Res. 2024 02 16; 30(4):729-740.
-
Li Y, Jacques S, Gaikwad H, Wang G, Banda NK, Holers VM, Scheinman RI, Tomlinson S, Moghimi SM, Simberg D. Inhibition of acute complement responses towards bolus-injected nanoparticles using targeted short-circulating regulatory proteins. Nat Nanotechnol. 2024 Feb; 19(2):246-254.
-
Souza R, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Waxman AB, Gr?nig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Lin J, Johnson-Levonas AO, de Oliveira Pena J, Humbert M, Hoeper MM. Effects of sotatercept on haemodynamics and right heart function: analysis of the STELLAR trial. Eur Respir J. 2023 09; 62(3).
-
Alshareef M, Hatchell D, Vasas T, Mallah K, Shingala A, Cutrone J, Alawieh A, Guo C, Tomlinson S, Eskandari R. Complement Drives Chronic Inflammation and Progressive Hydrocephalus in Murine Neonatal Germinal Matrix Hemorrhage. Int J Mol Sci. 2023 Jun 15; 24(12).
-
Hoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV, Preston IR, Souza R, Waxman AB, Gr?nig E, Kopec G, Meyer G, Olsson KM, Rosenkranz S, Xu Y, Miller B, Fowler M, Butler J, Koglin J, de Oliveira Pena J, Humbert M. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med. 2023 04 20; 388(16):1478-1490.
-
Chen TT, Greene MM, Everitt MD, Simpson KE. Basiliximab as maintenance immunosuppression in heart transplant recipients: A single pediatric center experience. Pediatr Transplant. 2023 03; 27(2):e14438.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|